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Abstract
Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer survivors. Despite
the proven efficacy, the non-adherence rate to therapy is still high. This study is aimed to examine women’s challenges
related to AET adherence and management. Semi-structured interviews were conducted with six Caucasian and six
African American breast cancer survivors who were prescribed for AET. The transcripts of audio-taped interviews were
qualitatively analyzed. Key themes were: 1) positive beliefs in AET, 2) uncertainty about long-term adherence, 3)
experiences with side effects, 4) forgetting and remembering, 5) other concerns and information needs, 6) potential
intervention format, and 7) culturally-coping among African American women. The findings provided insight into
women’s experiences and beliefs and how these behaviors might influence AET adherence. Although most women in
this study took AET as prescribed, many experienced a range of side effects and emotional distress, often without
seeking support or help. New models of programs to promote adherence, support symptom management, and ultimately
improve survival are critically needed. Developing culturally sensitive interventions for African American women is
desirable.
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Introduction
Both national and international guidelines have
recommended the long-term use of tamoxifen and
aromatases inhibitors (AIs) for breast cancer surveillance
management over the past few decades 1,2, and recently,
updated guidelines recommended 10 years of adjuvant
endocrine therapy (AET) in women with hormone
receptor-positive breast cancer 3, approximately 75-80% of
all breast cancer cases. Despite significant implications for
survival, adherence to AET, which is prescribed as a daily
oral tablet, is not optimal with the rate of nonadherence as
high as 59% for tamoxifen and 50% for AIs in some
studies 4. The cost of non-adherence to AET is significant
resulting in lost quality-adjusted life-years, increased
medical costs, and increased mortality, highlighting the
importance of developing adherence-promoting
interventions for this fast-growing population 5.

Breast cancer survivors have consistently reported that
severe adverse events and side effects, or concerns of their
development, are reported as a major barrier to
discontinue AET 6-13. Common side effects of tamoxifen
include gynecological symptoms such as vaginal bleeding
and discharge 11. AIs use may be accompanied by
musculoskeletal problems (i.e., arthralgia and
osteoporosis), cardiovascular effects, and sexual
dysfunction 11,14. Both therapies are associated with an
increase in vasomotor symptoms (i.e., hot flashes) and
cognitive impairment 11. Emerging quantitative studies
have linked factors of cost, doctor-patient communication,
health beliefs, fear of recurrence, self-efficacy, and lack of
information and social support to intentional nonadherence 15,16,17,18. To date, qualitative studies in
adherence research in patients taking oral anticancer drugs
are emerging but still limited. Gaining an in-depth
knowledge of the important factors that contribute to
women’s beliefs about the use or discontinuation of AET
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will allow us to develop intervention strategies promoting
women’s long-term adherence. Further, studies have
reported that compared with other racial/ethnic groups,
African American women have a higher rate of
discontinuation of AET treatment, which might contribute
to the differences in breast cancer mortality between
African American and White women 1, 2, 21. Thus,
understanding African American women’s unique
experience and developing tailored strategies to enhance
adherence to AET may help reduce disparities in breast
cancer outcomes between African American and White
women.
The goal of this qualitative study is to investigate women’s
barriers and facilitators to their adherence to AET and
experiences with AET-related symptoms, and to explore
any racial differences between Caucasian and African
American women in their experiences and needs.

Methods
Sample

Participants were recruited from Fox Chase Cancer Center
(FCCC) in Philadelphia, Pennsylvania, USA. Participants
were women who had been diagnosed with primary breast
cancer and had been prescribed Tamoxifen or AI between
one and five years after primary treatment completion.
Women taking endocrine therapy as part of treatment for
metastatic disease were excluded, as this study focused on
the perspectives of women taking AET to prevent
recurrence. African American women were purposively
sampled for the study. Sixteen women were approached
and screened for the study; two ineligible, two with no
interest, resulting in a total of six White and six African
American women participating in the interview.
Table 1 summarizes participant’s demographic and
medical characteristics (n=12). The mean age of
participants was 52 years (range 33-72). The majority of
the participants had some college (66.7%), reported an
annual household income of more than $30,000 (58.4%),
were unemployed (66.7%), were married (66.7%). Seven
women were diagnosed either with stage II or stage III
breast cancer (58%) and the majority completed
chemotherapy (88.3%). Five women were prescribed
Tamoxifen and seven were prescribed an AI daily. In
average, women had been taking AET for two years.
While taking AET, four women stated they never missed
their AET tablets but seven reported they had occasionally
missed their tablets. One women had stopped AET
temporarily and another stopped permanently following
her own volition.

Procedures

The study was approved by the FCCC Institutional Review
Board. Recruitment of study participants occurred
between June and December 2014. Women were recruited
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through clinician referral, study registry, and in person
approach in medical oncology practices. Eligible women
signed a consent form and completed a short demographic
and medical characteristics survey before the interview.
Interviews were conducted by the lead researcher (KYW)
or the trained research coordinator (RS) in a private
consultation room. Interviews lasted between 20 minutes
and 1 hour. All participants received a $10 gift card for
their time and effort.

Measure

The interviews were semi-structured and informed by
topics from two recent review of factors associated with
AET use 19,20. The interview guide was designed to probe
topics on their understanding and expectations of AET,
their experience with taking AET as prescribed, their
experiences with AET-related side effects, and their
suggestions on how to improve AET adherence and
symptom management.

Analytic Strategies

Interviews were recorded, transcribed and checked for
accuracy. Two phases of analysis were conducted. Initial
coding was carried out using an a priori coding scheme
based on the interview guide questions 21. After the first
round of coding, a research team group discussion was
held to elicit new themes emerging from the data and to
further refine the coding framework to include sub-themes
that describe more concrete units of the higher-level
themes. Themes and sub-themes were iteratively extracted,
discussed, and agreed on by all research team members 22.

Results
Analysis identified seven themes: 1) positive beliefs in
AET; 2) uncertainty about long-term adherence; 3)
experiences with side effects; 4) forgetting and
remembering; 5) other concerns and information needs; 6)
potential intervention format and 7) coping among African
American women.

Theme 1: Positive Beliefs in AET

Reasons to take AET was greatly shaped by
participants’ perceptions and beliefs about the
benefits of the therapy among this small group of
women who adhered to AET.
For survival. Most women stated that they knew the
therapy was important for their long-term survival,
and that was the reason for taking their prescribed
AET.
The oncologist explained to me the benefits long term
of taking it, and that is why I continued to take it.
[3-year survivor, White]
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Table 1. Demographic and Medical-Related Characteristics of Participants
Characteristics
n (%)
Age (Mean, SD) (range 33-72)
Education
Some college
College complete
Household income
< $30K
$30K to $60K
$60K and above
Employment
Employed
Unemployed
Retired
Marital status
Married
Married separated/divorced
Never married
Breast cancer stage
I
II/III
Treatment completion
Lumpectomy
Mastectomy
Chemotherapy
Radiation
AET medication
Tamoxifen
AI: Exemestane
AI: Letrozole
AI: Anastrozole
Years on AET (Mean, SD)
1 year
2 - 3 years
4 - 5 years
Ever miss a tablet while taking it
No
Yes
Unsure
Currently taking
Yes
Stopped temporarily
Stopped permanently

Total
n = 12
52 (11.8)

White
n=6
55 (6.0)

African American
n=6
50 (14.5)

8 (66.7)
4 (33.3)

4 (66.7)
2 (33.3)

4 (66.7)
2 (33.3)

5 (41.7)
5 (41.7)
2 (16.7)

2 (33.3)
2 (33.3)
2 (33.3)

3 (50)
3 (50)

4 (33.3)
7 (58.3)
1 (8.3)

2 (33.3)
4 (66.7)

2 (33.3)
3 (50)
1 (16.7)

8 (66.7)
2 (16.7)
2 (16.7)

6 (100)

2 (33.3)
2 (33.3)
2 (33.3)

5 (41.7)
7 (58.3)

2 (33.3)
4 (66.7)

3 (50)
3 (50)

7 (58.3)
4 (33.3)
10 (83.3)
9 (75)

2 (33.2)
3 (50)
5 (83.3)
3 (50)

5 (83.3)
1 (16.7)
5 (83.3)
6 (100)

5 (41.7)
2 (16.7)
2 (16.7)
3 (25)
1.9 (1.2)
6 (50)
5 (41.7)
1 (8.3)

2 (33.3)

3 (50)
2 (33.3)

4 (33.3)
7 (58.3)
1 (8.3)
10 (83.3)
1 (8.3)
1 (8.3)

I know it is one of the things that you have to do or
you don’t have to, but I choose to based on the
research. It is kind of what it is to survive. [1-year
survivor, White]
Benefits outweigh the risks. Many women spoke
about their fear of cancer recurrence motivating them
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2 (33.3)
2 (33.3)
1.8 (1.6)
4 (66.7)
1 (16.7)
1 (16.7)
3 (50)
3 (50)

1 (16.7)
2 (0.9)
2 (33.3)
4 (66.6)
1 (16.7)
4 (66.7)
1 (16.7)
1 (16.7)

1 (16.7)

to take their AET medication regardless of the side
effects. They believe the benefits of their therapy
outweigh the risks.
I guess the benefits, in my opinion, outweigh the risk
and the side effects. [1-year survivor, White]
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Personally, I thought it was to my benefit for me to
take the medication even with the side effects. [4year survivor, African American]
While I am on it, the cancer won’t come back. That
is the reason why I am taking it and going through
what I am going through because I don’t want the
cancer to come back. [4-year survivor, African
American]
Extra protection. Some women perceived taking
AET after primary treatment as a maintenance drug.
This makes them feel that they have extra protection
against a recurrence of breast cancer, and that they
have control over their health.
I feel it is a maintenance drug after having breast
cancer. [1-year survivor, White]
I feel better knowing that I am on something that I
feel is preventive, so I guess I feel a little safer taking
something rather than being completely without
treatment. [2-year survivor, White]
Theme 2: Uncertainty about Long-Term Adherence

Is 10 the magic number for Tamoxifen? Although
being currently compliant, some women who have
been on Tamoxifen have expressed their uncertainty
or confusion about extending the use of Tamoxifen
from 5 years to 10 years, given the new updated
guideline. Two women explicitly spoke about their
concern of the increased risk of uterine cancer with
possible longer duration of Tamoxifen use.
I am starting to hear that you might benefit from
being on it longer, so when I hit my five-year mark,
that will be a big concern … Going off of it is going
to be a concern because you kind of feel like once you
go off medication, what’s going to happen? So, it is
like a roller coaster of emotions … I am concerned
about effects that can happen down the line ... I
think I have read that it can cause thickening of your
uterine lining. [2-year survivor, African
American]
I was told two different time frames. One time, I was
told 5 years and then the next time, 10 years …
they told me we would look at it when I get closer to
the 5-year point … my concern is I have an
increased risk of uterine cancer while on it. [1-year
survivor, White]

107

Uncertainty in the context of not knowing. Women
talked about their lack of information on the
medication itself and related side effects, especially
the impact of the medication in the long term.
Uncertainty about the impact of the medication on
survival or adverse effects might contribute to
potential nonadherence beliefs.
Is this just the side effect I will have for five years or
will there be other side effects that will follow, or how
is it going to work afterward, I do not know. I am
not going to drop the medicine yet, but honestly, I
don’t think I am going to take it for 5 years. [1year survivor, White]
I do not have much information on the medication,
like the side effects and like the outcome…when you
take an antibiotic and you take it for 5 days, and
you start feeling better … it’s like I am taking this
hoping that it will repress the cancer cells, but do I
have or don’t I have cancer cells? I am just taking it
in the dark. [2-year survivor, African
American]
Theme 3: Experiences with Side Effects

Although most women reported taking their
medication as prescribed, many described their
challenging experience with side effects both
emotionally and physically.
Frustration with symptoms. Several provided
graphic descriptions of extreme symptoms including
hot flashes and night sweats, joint and bone pains,
vaginal dryness, insomnia, weight gain, diarrhea,
fatigue, and mood swings.
I get very, very hot like in my face and all around my
body … I have to take all my covers off immediately
... and like in ten minutes, I get this chill going
through my body … when it starts, it goes back and
forth for a while. [1-year survivor, White]
I had insomnia for about three months. I couldn’t go
to sleep. I slept for maybe two to three hours within a
day. [2-year survivor, African American]
I have the ups and downs ... you know, one day I
am up and one day I am down ... I can feel like
when I am becoming angry, and I don’t know why,
or if I am just feeling like depressed. [2-year
survivor, African American]
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I have new aches, I have back pains, I have
headaches. I could be fine today and tomorrow, I can
be sick as a dog. [4-years survivor, African
American]
Impact of symptoms. Some women described the
profound impact that side effects had on their daily
lives. Side effects, such as fatigue, impede women in
performing their normal daily activities.
I was never told that I would have been incapacitated
to the point where it would be difficult getting out of
bed to shower and dress and to just do those things in
normal daily living. [2-year survivor, African
American]
I am going through so much with this new medication
that I am taking, that I have not worked a full week
since this year. [4-year survivor, African
American]
Emotional adjustment. Some described the impact
of side effects on their emotional wellbeing. Their
distress was also caused by the deterioration of their
body image and impaired efficiency because of
tiredness and hot flushes.
I was psychologically unprepared to the extent of the
side effects because I have been an extremely busy,
active person … but the medication did something to
me emotionally where I couldn’t do it ... so not being
able to function in the capacity that I am used to
doing really affected me psychologically [4-year
survivor, African American]
It affected my skin, became dry, my hair became
brittle ... everything is dropping and sagging. The
emotional effects of going through menopause for me
was the most challenging, where the physical effects
not so much for me. [2-year survivor, African
American]
The side effects caused a lot of my negative attitude.
[1-year survivor, White]
Coping with symptoms. Several women reported
that their providers suggested they take the
medication at night to avoid the symptoms. Women
also reported using supplements to cope with
symptoms.
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The nurse recommended taking it at night because
with the symptoms that can happen, it might be more
tolerable while you are sleeping over night as opposed
to in the middle of the day, so I take mine before I go
to bed and that did work for me. [2-year
survivor, African American]
I started to take the vitamin B. It helped my energy
level. I am still tired, but not as tired as I was a few
months ago. [2-year survivor, African
American]
I take this with a vitamin D 200 for my bones and
my age. [4-year survivor, African American]
I have a lot of bone pain, and I do have arthritis and
my calcium level is low, so I am taking calcium pills.
[4-year survivor, African American]
About two months of being on the medication, I
began to have chronic diarrhea. I started to take a
probiotic and it helped. [3-year survivor, White]
Theme 4. Forgetting and Remembering

Unintentional non-adherence. Women reported
unintentional non-adherence, which was usually a
result of an unestablished routine at the initiation of
the therapy or an interrupted routine because of
change of personal schedule. Feeling tired or sick was
also reported interfering with staying on their
medication schedule.
At the beginning, I didn’t remember if I took it or
not. [4-year survivor, African American]
Sometimes, it takes a while to get into the routine to
remember to take it. I am sure there were many days
that I missed, one here and there. [5-year survivor,
White]
When I am out maybe on the weekend or at a
conference. I did not bring my pill bottle with me. It
is like a break of my normal routine. [2-year
survivor, African American]
Sometimes, I missed a day or two because I get too
tired and I fall asleep. [2-year survivor, African
American]
Strategies to aid in remembering. Women reported
different strategies that helped them remember to
take their medications including using visual cues
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(e.g., by the bed), external aids (e.g., a reminder app),
and organization medicines (e.g., a pillbox). As a
result of implementing these strategies, women were
able to integrate taking their medication as part of
their daily routine.
I take it at night. I just remember to take it like a
birth control pill, that is how I look at it. [2-year
survivor, African American]
I know every time that I eat lunch, I take my
medication. I keep the bottle in my pocketbook, so
when I go to lunch, I take my phone, and when I
take my phone, I always see the medication in my
pocketbook. [4-year survivor, African
American]
My bottle is right next to my bed, so typically, like
10’oclock is when I start winding down, so that is
sort of my routine. [2-year survivor, African
American]
I have a pillbox, and basically, my reminder is when
I give my husband his insulin at 9 and I take my
pill. [1-year survivor, White]
I have an app on my phone. At the time, the app
sends you a reminder and if you don’t click I took
my medication in like 15 minutes, it plays a tune.
[1-year survivor, White]
I take it every night after dinner, as a joke, they call
it my staying alive pill, and we always joke about it
so I took it. [2-year survivor, White]
Theme 5. Other Concerns and Information Needs

Impact of medication on fertility. A main concern
that was reported by younger participants is the
fertility issue. They were worried about their fertility
status and wanted a clear understanding on the
impact of the medication on family planning.
Me and my husband discussed he wants another
baby, and with me being on the Tamoxifen, they told
me I couldn’t have children. So that’s the only thing
that is a big problem in my personal life, that might
be one of my questions when I go to the doctor. [2year survivor, African American]
I know that I have to be on it for 10 years, but what
I want to know is, if after 10 years, would I be able
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to become pregnant? [2-year survivor, African
American]
Drug interactions. Given comorbidities are not
uncommon among cancer patients, some women
expressed their concern about the timing of taking
their AET in relation to other chronic disease drugs
and any potential drug interaction that they should be
aware of.
If someone is new to the Tamoxifen and they are
taking different medications, the hospital should say
okay this drug is compatible with this drug so that
way, for people who take different medication,
Tamoxifen might not be good for me or I can’t mix
the medication. [2-year survivor, African
American]
I normally take Arimidex in the morning after
breakfast, then I normally take my blood pressure
medications in the evenings because I don’t know, I
haven’t been told if there are any contraindications to
taking all of them together. [2-year survivor, aged
62, African American]
Nutrition and Diet. Some participants discussed
their desire to receive information on nutrition and
to have opportunities to discuss their dietary
questions with a dietitian. They would like to receive
practical advice on food selection during AET.
Dietary information includes types of foods to eat to
minimize side effects from AET, particular vitamins
and minerals to help prevent cancer recurrences, and
general nutrition information to feel better.
One thing that was lacking with the medication was
the proper nutrition [4-year survivor, African
American]
I would love to be able to be in touch with researchers
who are doing work with natural remedies to prevent
recurrence of breast cancer. I would love to be in
touch with a nutritionist to learn how to eat well.
[2-year survivor, African American]
Theme 6: Potential Intervention Format

Following the interview about AET experiences and
concerns, survivors were asked “how” to get the
support or information they desire.
Intervention delivery modality. When discussing
what could have helped women learn about and
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continue to use AET, some participants brought up
the idea of using portal websites that present
individual prescription and related information that
can be easily accessible. Using a portable feature on a
cell phone or using text messaging was also
mentioned as a potential modality for delivering any
medication tips and reminders.
If you are able to have like our medications in a
portal website where you can go to and there would be
resources available specific to the prescriptions that
you are on and symptoms that you can kind of look
up [2-year survivor, African American]
If there are any tips to help me to remember to take
it on a daily basis instead of skipping occasionally.
Some reminder, like portable on my phone. [5-year
survivor, White]
Because if I do forget, text messages would be an
extra back-up to remind me. [2-year survivor,
White]
Long-term follow-up. While some women reported
receiving information about AET from their
providers at the time of treatment initiation, they also
expressed that it was difficult to recall the
information they had initially received, or it was too
overwhelming to comprehend the information at the
time. The possibility of a long-term follow-up to
reiterate the importance of AET and potential new
side effects was suggested.
Maybe after a year or two or maybe two or three
years, another reminder of possible side effects. I
know they gave me a handout, but I don’t know
what I did with it. [5-year survivor, White]
My provider gave me a lot of information which I
was not able to truly initially comprehend I was so
upset. [4-year survivor, African American]
Theme 7: Coping Among African American Women

Religion and spiritual coping. Our data suggest that
religion and spirituality might play a major role in the
lives of our African American participants. In our
study, African American women coped with their
symptoms and fear of recurrence through their
religious and spiritual beliefs. Their positive
perceptions were empowered by their faith in God.
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I prayed about it (Tamoxifen) and went to God, and
I knew that everything was going to be ok. [2-years
survivor, African American]
Through prayers, lots of meditation, it is a lot better,
but I am still dealing with the emotional part of it
(side effect). [4-year survivor, African
American]
I have a strong belief in God. I have a strong belief
in prayer. I feel that when I found my tumor myself
is a gift from God. [2-year survivor, African
American]
Peer-support. Relationship with other breast cancer
survivors was reported important to most of our
African American participants. In some instances,
they shared information and support with other
breast cancer women, either one-on-one or through
support groups.
I have started a breast cancer survivor group at my
church for women diagnosed and going through the
daily day-to-day problems. [2-year survivor,
African American]
Talking to some close friends who have gone through
the medication. I am involved in my church cancer
program, and I am asked to comment on it so other
people have been led to me because of my experience.
[4-years survivor, African American]
I found that the Facebook group that I belong to is
really helpful for me, you post things or I see other
women posting things, and everybody kind of chimes
in and that’s helpful. [2-year survivor, African
American]
Discussion
The aim of this study was to explore and understand
women’s experiences and adherence behaviors after
initiation of AET from 1 to 5 years. As found in other
studies, most of the women interviewed in this study
believed that taking the prescribed AET would improve
their survival, despite the presence of side effects. This
finding is consistent with the “necessity-concern” model 23
in that women who adhere to the therapy trusted and
believed that the medication will prevent the recurrence of
cancer, which to them was a motivation to adhere to the
therapy although they had to tolerate significant side
effects. The type and nature of AET-related side effects
reported in the interviews were consistent with previous
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clinical reports in the literature 24,25. However, women
reported receiving little support from their providers and
the magnitude of symptoms sometimes strongly interfered
with their daily activities. Further, providers might perceive
side effects that affect the quality of life of patients taking
AET are usually not life-threatening and differ from those
that providers are mostly concerned about 26. Therefore,
AET-related symptom information might not be discussed
with patients comprehensively. Unbiased and objective
information about AET side-effects for patients is desired
and critical. As the recommended duration of AET is
being extended 27, management of these symptoms is
becoming increasingly important because these side effects
can adversely impact both patient’s quality of life and
adherence to prescribed treatment. Future research needs
to develop effective interventions to address a patient’s
doubt about the necessity for AET and concerns about
side effects to enhance adherence.
Most women in our study believed that they were adherent
and had implemented strategies in establishing a daily
routine to help them remember to take their tablets. These
routines generally consisted of a combination of keeping
the medication somewhere they would be seen and/or
taking the medication at a very specific time each day.
Occasionally, forgetfulness usually occurred when the
routine was not established yet (e.g., at the beginning of
treatment initiation) or when the routine was interrupted
(e.g., on vacation). Therefore, future research needs to
inform initiation of care, where patterns of behaviors are
established and carried out through the entire AET
treatment regimen.
While patients of all ages may contend with challenges
surrounding their treatment, younger women, who are
interested in having biological children after treatment,
face added complexity. Consistent with previous studies
that younger women have questions regarding fertility 28,
our data suggest that some younger women might have
unmet information needs about their fertility status during
or after AET treatment. Interest in receiving fertilityrelated information was even identified among those who
already have children at diagnosis, suggesting the
importance of not overlooking the fertility issue among
breast cancer patients with children. Clinicians need to be
aware of and have an understanding for their younger
patients’ values regarding childbearing in order to assist
them to make truly informed decisions and, thereby,
adhere with their AET treatment.
Cancer patients often receive numerous medication,
including anticancer drugs and drugs to treat comorbid
conditions. These multiple treatments increase patient’s
uncertainty about drug interactions and any potential
adverse effects, as suggested in our patient’s responses.
Considering that a significant number of patients with
hormone receptor-positive breast cancer would use AET
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treatment in the future, communication about the safety
use of other drugs in relation to AET is an important part
of survivorship care. Furthermore, our findings are also
similar to those of previous studies that showed breast
cancer patients desire information regarding nutrition and
diet 29. In particular, some of our participants expressed
their strong desire to receive information about what to
eat that would ease the AET-related side effects and
improve their survival. Despite the availability of a range
of resources and information sources that exist on the
subjects of diet and nutrition in cancer, breast cancer
patients continue to report unmet needs in the area of diet
30,31, perhaps indicating available information lacks
specificity (e.g., in the context of AET). Our findings
suggest an increase in provision of diet and nutrition
information during AHT is needed.
Although previous interventions with patient educational
materials and phone reminders have had minimal success
in increasing AET adherence 32-34, as some of our
participants mentioned, future interventions should
consider how to use technology (websites or text
messaging or other “out-of-the-box” approaches) to
promote AET adherence. Text messaging is one of the
most accessible forms of mHealth communication, and
evidence is emerging on the use of text messaging for a
wide range of health and behavioral programs including
medication adherence 35. Text messaging might be an
effective modality to promote AET adherence, as it can be
integrated into women’s daily life and adapted to individual
needs in real time 36. Using web-based or mobile platforms
to offer medication reminders, symptom management,
compliance comparison with the patient population, and
survival rate improvements could be used to encourage
women to comply with treatment recommendations.
Future research should aim to quantify preferences for
information tools and communication strategies in a larger
sample with a focus on tailoring the interventions for
women with different information needs and cultural
ethnic background. Longitudinal interventions with longterm follow-ups at different time points to reiterate the
importance of AET and strategies for managing new side
effects would be also important, as updated guidelines
recommend consideration of 10 years of AET in women
with hormone receptor-positive breast cancer 27.
Our findings suggest that religion and spirituality were
important components in our African American women’s
breast cancer experience. Previous research showed that
faith in God helped African American women cope during
and after treatment, as they believed they could endure
their treatment and related side effects and ultimately
survive the disease 37,38. Further, the benefit of peercommunication was suggested in our African American
subgroup. Therefore, future interventions targeting
African American breast cancer women might want to
consider utilizing spiritual ties or peer-led approaches for
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strengthening AET beliefs and promoting its adherence.
Additional research focusing on African American breast
cancer women’s experience with AET is needed as our
sample was limited.

provide opportunities for targeted interventions to
improve survivor’s experience and symptom management,
which could ultimately improve adherence, quality of life,
and survival.

Our study was not without limitations. Our sample size
was small and relatively well-educated, therefore, the views
expressed by women in our study were not representative
of the entire population of women receiving AET for their
breast cancer. Future research should aim to extend our
findings across a more diverse sample including different
ethnic groups and low-literate populations. As identifying
the cultural factors that contribute to ethnic variation in
AET adherence is important, we also want to emphasize
that individual patient’s needs might be different, requiring
personalized care and support. The majority of the women
in our limited sample adhered to the AET so far, thus,
findings from their experience might not be informative
about non-adherence. Women who stopped AET
completely were under-represented in this study (only one
in our sample). It is possible that we were not able to reach
non-adherent patients due to their loss for follow-up
survivorship care or the lack of knowledge of their
clinicians. Further qualitative studies targeting women who
are known to be non-adherent would enhance the
knowledge base in this area. Further, participants in this
study were all recruited at a cancer center, thus participants
were likely to respond to some doctor-patient relationship
questions with socially desirable answers. The results
obtained by the present study might be influenced by
recollection bias. Prospective studies of women’s AETrelated needs and how their experience change over time
are critical.
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